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Immunostimulatory oligodeoxynucleotides (ODN) are effective adjuvants in the induction of humoral and cellular
immune responses when administered parenterally with antigen. The skin has recently become a target organ for
the design of non-invasive vaccine technologies. Using ovalbumin (OVA) as a model antigen, we demonstrate that
the application of ODN sequences to tape-stripped skin promotes the induction of potent cytotoxic T lymphocyte
(CTL) responses to co-administered peptide. Induction of peptide-speciﬁc CTL required the presence of CpG motifs
within the ODN. CTL afforded tumor protection against a tumor expressing an immunodominant OVA CTL epitope.
CTL could also be induced to whole protein administered onto the skin. Differential CpG sequence activity was
noted with respect to the induction of CTL to epicutaneous protein with an ODN sequence containing a poly-G motif
having an optimal effect. Peptide-speciﬁc CTL could be detected in the peripheral blood as early as 6 d after a
single immunization. These results highlight the potential of the bare skin as a route for vaccine development and
indicate an important role for immunostimulatory ODN as adjuvants to generate functional CTL with the help of the
skin immune system.
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Vaccination is a cost-effective method for promoting health.
Most vaccination protocols, however, rely on parental
administration of antigen entailing the use of needles with
the attendant costs of trained personnel and the risk of
blood-borne pathogen transmission. Further, as the devel-
opment and availability of new vaccines proceeds, children
are exposed to needles more frequently and this associa-
tion with pain and discomfort may decrease compliance.
There has thus been interest in the development of non-
invasive routes of delivery. In particular, the use of the skin
as target organ for vaccine design (Babiuk et al, 2000;
Hammond et al, 2001; Partidos et al, 2001) has been
spurred by the fact that epidermal dendritic cells (DC),
termed Langerhans cells, are among the most efficient
presenters of antigen to the immune system (Romani et al,
1989; Celluzzi and Falo, 1997) and are abundant in the skin
(Bergstresser et al, 1980). Recent interest in the use of the
skin as a vaccination site has followed the observations that
repeated epicutaneous exposure to protein antigens could
induce dominant Th2 T cell and antibody responses (Saloga
et al, 1994). Glenn and colleagues have demonstrated that
cholera toxin (CT) (Glenn et al, 1998a) and other bacterial
toxins (Glenn et al, 1999) can be used as transcutaneous
adjuvants for protein immunization through the skin.
Repeated application of proteins on the skin in this manner
was found to result in the generation of serum and mucosal
IgG and IgA antibodies capable of mediating protective
immunity against mucosal (Glenn et al, 1998b) and systemic
(Glenn et al, 1999) toxin challenge. Induction of antigen-
specific CD4þ T cell responses with a Th2 bias in this
manner has also been demonstrated (Beignon et al, 2001;
Hammond et al, 2001).
Cytotoxic T lymphocytes (CTL) are crucial in the
mammalian immune defense against tumors and viruses
(Bangham and McMichael, 1989; Boon et al, 1994). A
limitation of current vaccine strategies, however, is the
inefficient priming of CTL (Steinman and Pope, 2002).
Unmethylated CpG dinucleotides flanked by certain bases
(CpG motifs) have been shown to be immunostimulatory
(Krieg et al, 1995; Sato et al, 1996; Klinman et al, 1997).
Synthetic oligodeoxynucleotides (ODN)-bearing immunos-
timulatory CpG motifs have been shown to potentiate CTL
responses to co-administered peptides or proteins emulsi-
fied in IFA and to promote survival in response to tumor
challenge (Krieg et al, 1995; Sato et al, 1996; Klinman et al,
1997). These motifs also allow the induction of CTL
responses to specific peptides in the absence of additional
adjuvant (Vabulas et al, 2000; Miconnet et al, 2002). Herein,
we explore the possibility that ODN can be used epicuta-
neously to promote the generation of CTL to co-adminis-
tered peptide or protein antigen. We find that ODN
sequences can be added, in an epicutaneous immunization
protocol, to either the model foreign protein ovalbumin
(OVA) or the immunodominant class I MHC-restricted
peptide derived from OVA to induce potent epitope-specific
Abbreviations: CT, cholera toxin; CTL, cytotoxic T lymphocyte; DC,
dendritic cell; FMOC, 9-fluorenylmethoxy carbonyl; MHC, major
histocompatibility complex; ODN, oligodeoxynucleotide; OVA,
ovalbumin; PE, phycoerythrin; SFC, spot-forming cells
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CTL responses that demonstrate protective activity in an
induced tumor model.
Results
ODN promote the generation of CTL to epicutaneously
administered peptide Contact hypersensitivity responses
to epicutaneously administered haptens such as dinitro-
fluorobenzene are mediated by the priming and effector
functions of CD8þ T cells (Bour et al, 1995). Further,
epidermal Langerhans cells can induce potent antigen-
specific CTL when pulsed with class I MHC-restricted
epitopes and adoptively transferred into naı¨ve hosts
(Celluzzi and Falo, 1997). We thus sought to induce CTL
by the epicutaneous administration of peptide. To study
epicutaneous CTL priming we chose to use OVA as a model
system as the immunodominant epitope of OVA (SIINFEKL)
presented in the context of the Kb MHC molecule is well
characterized (Rotzschke et al, 1991). This system was also
chosen as the growth of OVA-bearing tumor cells (EG7; EL-
4 thymoma cells transfected with OVA cDNA) (Moore et al,
1988) allows an in vivo read-out of the efficacy of CTL
induction.
Tape-stripping is a simple method to remove the
epidermal barrier of the stratum corneum. We therefore
immunized mice immediately following tape-stripping with
either 25 mg OV8 peptide alone or with 100 or 500 mg of
immunostimulatory ODN. We used a sequence well known
to induce Th1 immunity, ODN-1826 (Chu et al, 1997). We
also tested a sequence, ODN-6295, that is complementary
to the initiation codon sequence of the proto-oncogene
c-myc and contains a 50 CpG motif that induces strong Th1
responses in mice (Mui et al, 2001). To quantitate the
generation of CTL in vivo, we used an ELISpot assay that
detects antigen-specific IFNg release by activated CTL
(Fig 1A). Mice were injected with live EG7 cells to generate
CTL as a positive control. Treatment with peptide alone
resulted in few OV8-specific SFC (6  3 SFC per 106 in the
lymph nodes and 6  5 SFC per 106 in the spleen, n¼3).
Immunization in the presence of ODN-1826, however,
resulted in a significant increase in OV8-specific SFC in
the lymph nodes at a concentration of either 100 mg
(268  90, n¼3, po0.05 compared with peptide alone) or
500 mg (495  40, n¼3, po0.001 compared with peptide
alone). To determine if CTL precursor cells were capable of
inducing mature, functional CTL, splenocytes were re-
stimulated in vitro with irradiated EG7 cells and then tested
for CTL activity in standard chromium release assays (Fig
1B). CTL activity against the OVA-bearing tumor, EG7, but
not against the control EL4 was generated following
epicutaneous immunization in the presence of 500 mg
ODN-1826 and less cytolytic activity was noted with 100 mg
ODN-1826. Although few peptide-specific SFC were de-
tected in the draining lymph nodes of mice immunized with
ODN-6295 and peptide (Fig 1A), CTL activity could be
generated from splenocytes of mice immunized with 500 mg
ODN-6295 (Fig 1B). It should be noted that CTL responses
were never observed when ODN in PBS was applied with
antigen to the skin without barrier disruption by tape-
stripping (data not shown) or when peptide was applied
without ODN. Thus, epicutaneous application of peptide to
tape-stripped skin, in the presence of ODN can induce CTL
to the applied peptide. The response is ODN concentration-
dependent. Different ODN sequences have varying ability to
enhance CTL generation epicutaneously to co-administered
peptide.
Class I MHC tetramers are novel reagents that allow the
rapid quantification of CTL frequencies immediately ex vivo
(Altman et al, 1996). The fraction of epitope-specific CTL
detected by ex vivo staining of blood lymphocytes for
tumor-specific CTL has been shown to correlate with the
Figure 1
Effect of oligodeoxynucleotides on the
induction of CTL by epicutaneous
immunization of mice with peptide
antigen. Mice were immunized with 25 mg
OV8 peptide applied to tape-stripped ear
skin and boosted 1 wk later. Immunization
was completed in the presence of either
100 or 500 mg ODN (6295 or 1826) with
the dose indicated in parenthesis. Mice
injected with a tumor cell line transfected
with ovalbumin (EG7) were used as a
positive control. One wk after boosting,
lymph node cells and splenocytes were
harvested and assayed for the presence
of CTL precursors using ELISpot (Panel A)
or standard CTL assay (Panel B). (Panel A)
Scatter gram of peptide-specific spot-
forming cells (IFNg-spots) detected in the
lymph nodes of immunized mice. (Panel
B) Chromium release assay: mice immu-
nized as in Panel A. Splenocytes were re-
stimulated in vitro prior to assay for
cytolytic activity. Data points correspond
to the average of triplicates from indivi-
dual mice and varied less than 10%.
These assays are representative of three
independent experiments.
CpG ADJUVANTS AND EPICUTANEOUS VACCINATION 1043122 : 4 APRIL 2004
fraction of such cells present in the spleen and lymph nodes
(Miconnet et al, 2002). As mice immunized with ODN-1826
and peptide showed an optimal CTL response, we used
Kb-OVA tetramers to further study the peripheral blood of
mice immunized with OV8 and ODN-1826. To study the
requirement for a CpG sequence in the immunostimulatory
effect of the ODN we also used ODN-1982, which has the
identical base composition as ODN-1826 without the CpG
motif (Fig 2). To determine if the ODN applied had a
systemic immunostimulatory effect or a local adjuvant effect
ODN was applied to the contralateral ear, at a site distant to
the peptide immunogen. Mice were immunized once,
boosted at 7 d, and bled at 12 d. The peripheral blood of
mice immunized with ODN-1982 and OV8 peptide con-
tained a low frequency of OV8-specific CTL (0.05% of
CD8þ T cells), similar to un-immunized controls. With
ODN-1826, roughly 20-fold more OV8-specific CTL were
detected (1.09% of CD8þ T cells). Application of ODN-1826
to the contralateral ear completely negated the adjuvant
effect indicating that there is no systemic immune activation
or adjuvant effect following the topical application of 500 mg
ODN-1826. Functional analysis of CTL precursors present
in the spleen using ELISpot assay confirmed the results
obtained by blood tetramer analysis demonstrating a 3-fold
increase in peptide-specific SFC when ODN-1826, but not
control ODN-1982 was co-applied with peptide immunogen
(Fig 2B). The application of ODN-1826 resulted in activation
of CD11chi DC in the draining lymph nodes when evaluated
at 20 h as evidenced by increased CD80 and CD86
expression when compared with DC from mice treated with
ODN-1982 (Fig 2C).
Epicutaneous immunization with peptide and ODN
affords tumor protection As an in vivo read-out of the
efficacy of CTL induction, we used the inhibition of the
growth of OVA-bearing thymoma tumor cells (EG7).
Immunization with OVA and adjuvant can diminish and
prevent the growth of EG7 tumor cells injected subcuta-
neously (Porgador et al, 1997). CT has been used as an
epicutaneous adjuvant to enhance antibody responses to
epicutaneously administered proteins (Glenn et al, 1998a).
CT has also been used to promote the generation of CTL
responses after mucosal immunization (Porgador et al,
1997). We have determined that CT can enhance the
induction of CTL to epicutaneously administered peptide
(Kahlon et al, 2003). To compare the ability of immunosti-
mulatory ODN and CT to provide tumor immunoprophy-
laxis, groups of eight mice were immunized epicutaneously.
Groups of four mice were bled on day 12 to document the
presence of OV8-specific CTL ex vivo. Mice then received
5  106 EG7 tumor cells subcutaneously and the growth of
resultant tumors was monitored for 3 wk (Fig 3). Mice
immunized epicutaneously with OV8 peptide in the pre-
sence of the ODN-1826 (0.82%  0.19% of CD8þ T cells,
n¼4, po0.05) demonstrated a significant increase in OV8-
specific CTL in the peripheral blood when compared with
sham immunized mice (0.11%  0.01%). Mice immunized
with either peptide alone (0.19%  0.03%, n¼4), peptide
with ODN-6295 (0.27%  0.08%, n¼4) or CT (0.48% 
0.04%, n¼4) did not have statistically significant differ-
ences in the frequency of OV8-specific CTL in the peripheral
blood when compared with the other groups. Concordant
with this, there was a significant inhibition of tumor growth
only in mice immunized with OV8 and ODN-1826 (Fig 3B,
p¼0.0006). To confirm that the inhibition of tumor growth
was secondary to a peptide-specific CTL response and not
due to an antigen non-specific mechanism, mice were
immunized with ODN-1826 and the tumor-expressed OV8
peptide or an irrelevant Kb-restricted peptide (2C) and
compared with mice immunized with OV8 peptide and
control ODN-1982 adjuvant. Significant numbers of OV8-
specific CTL were only found in the blood of animals
immunized with OV8 and ODN-1826 (Fig 3C). Similarly,
tumor growth inhibition was only noted in mice treated with
Figure2
Effect of oligodeoxynucleotide sequence and location of applica-
tion on the generation of CTL to epicutaneously administered
peptide. Mice were immunized with 25 mg OV8 peptide on tape-
stripped ears in the presence of the 500 mg dose of ODN-1826 or with
the control ODN-1982, boosted in similar fashion at 1 wk (day 7) and
bled at 12 d following the initial immunization. ODN was applied either
with the peptide immunogen or separately on the contralateral ear
(Contralat.). (Panel A) Representative dot-plots of peripheral blood
lymphocytes demonstrating CD8 expression and Kb-OVA tetramer
staining. The numbers represent the percent Kb-OVA-specific CD8þ T
cells among all CD8þ T cells detected. (Panel B) Bar graph of peptide-
specific IFNg-spot-forming cells (IFNg-spots) detected in the spleens
from individual mice immunized as in Panel A. (Panel C) Draining lymph
node dendritic cell (CD11chi) expression of CD80 and CD86 20 h
following application of either ODN-1826 or ODN-1982 to the ear.
These assays are representative of two independent experiments.
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OV8 peptide and ODN-1826 adjuvant (Fig 3D). Thus
epicutaneous immunization with peptide in the presence
of ODN-1826 induces functional CTL in vivo and the
presence of these CTL correlates with an inhibitory effect
on cognate peptide-bearing tumor growth.
ODN sequences differentially promote CTL induction to
an epicutaneously administered protein or peptide Epi-
cutaneous immunization using whole proteins has been
demonstrated to result in the generation of antibody
responses when accompanied by the application of
bacterial-derived adjuvant. CTL priming to epicutaneously
applied peptide following tape-stripping has been demon-
strated previously but epicutaneous protein administration
has only resulted in negligible CTL responses. We have
recently demonstrated that the co-administration of CT with
whole protein to tape-stripped skin can induce robust CTL
responses (Kahlon et al, 2003). We therefore sought to
determine if co-administration of immunostimulatory ODN
sequences with OVA would enable local protein uptake and
processing to result in priming of OV8-specific CTL. To this
end, mice were immunized and boosted once with 500 mg
OVA protein and ODN-6295 or ODN-1826, or their control
sequences ODN-6300 or ODN-1982, respectively. Follow-
ing intradermal immunization with peptide and ODN-1826,
the frequency of peptide-specific CTL peaks at 7 d
(Miconnet et al, 2002). We determined the frequency of
OV8-specific CD8þ Tcells after a single immunization and a
boost (Fig 4). Surprisingly, ODN-6295 generated more CTL
than ODN-1826 when using a protein as an immunogen and
we could detect OV8-specific CD8þ T cells 6 d after a
single epicutaneous immunization. A second ‘‘booster’’
immunization at 7 d enhanced the number of CTL in the
peripheral blood when analyzed at day 12. To confirm the
differential activity of ODN-6295 on a protein versus peptide
immunogen, mice were immunized with either 500 mg OVA
protein (  12 nmol) or 25 mg of OV8 peptide (  24 nmol)
and 500 mg of ODN (either ODN-6295, or ODN-1826). To
determine if functional CTL precursors were generated,
splenocytes were then stimulated once in vitro and tested in
a chromium release assay (Fig 4B). Epicutaneously admi-
nistered peptide or whole protein could induce potent CTL
activity. Again, the optimal adjuvant immunostimulatory
sequence for OVA protein immunization (ODN-6295) dif-
fered from the optimal sequence for OV8 peptide immuni-
zation (ODN-1826). Mice immunized with protein and the
control ODN (1982 or 6300) did not generate CTL activity
(data not shown). Thus, the two ODN sequences we have
studied differentially promote CTL induction to an epicuta-
neously administered protein or peptide.
Figure 3
Effect of epicutaneous immunization on tumor immunoprophylaxis and correlation with ex vivo enumeration of antigen-specific CTL
among peripheral blood lymphocytes. Mice were immunized epicutaneously and boosted once with OV8 peptide alone or with either 25 mg
cholera toxin (CT) or 500 mg ODN (6295 or 1826). Mice treated with PBS were used as a negative control. Mice were bled on day 12, prior to
inoculation with an OVA-bearing tumor. The percent of OV8 peptide-specific CTL among the CD8þ T cells in peripheral blood lymphocytes was
determined in individual mice using a OVA-Kb tetramer. A scatter plot of the results for four mice per group is represented in Panel A. The means
were significantly different (p¼ 0.019, the Kruskal–Wallis test) with a post hoc comparison between PBS and 1826 (500) demonstrating a significant
difference (po0.01, Dunn’s multiple comparison test). Tumor volumes were then measured serially in groups of eight mice and are depicted as a
function of time in Panel B. Error bars represent SEM. The differences between groups were significant (p¼ 0.0006) with a post hoc comparison
using a Bonferroni adjustment revealing a significant difference between PBS versus OV8-1826 (p¼0.002) and between OV8-1826 versus OV8
(p¼ 0.002). (Panel C) Mice were immunized with OV8 peptide or the irrelevant Kb-restricted control peptide 2C together with ODN-1826, or with OV8
peptide and the control ODN-1982. Mice were bled on day 12, prior to tumor inoculation. A scatter plot of the results of three mice per group is
shown. There was a significant difference between groups (p¼0.02, the Kruskal–Wallis test) with a significant difference between OV8þ1826
versus naı¨ve (po0.05) and OV8þ 1826 versus OV8þ1982 (po0.05). Mice were then inoculated with an OVA-bearing tumor. Tumor volumes were
then measured at day 14. The average of tumor sizes in individual mice are indicated in Panel D with error bars indicating SEM. There was a
significant difference between OV8þ1982 versus OV8þ1826 (p¼ 0.002, unpaired T test) and 2Cþ1892 and OV8þ 1826 (p¼ 0.001, unpaired T
test). Results are representative of two independent experiments.
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Discussion
In this study, we demonstrate that topical application of
immunostimulatory ODN to tape-stripped skin enhances
the generation of CTL to epicutaneously applied peptide or
protein antigen. As ODN sequences with CpG motifs are
known to activate cutaneous DC (Jakob et al, 1998), to
enhance their migration from the skin (Ban et al, 2000) and
to stimulate IL-12 production (Jakob et al, 1999), these
observations are consistent with the hypothesis that
epicutaneously administered protein or peptide antigen is
taken up by resident cutaneous DC (either Langerhans cells
or dermal DC) and transferred to the draining lymph nodes
for presentation to naı¨ve T cells. ODN can exert a moderate
adjuvant effect in the generation of humoral immune
responses to topically applied toxins such as diphtheria
toxoid in the absence of tape-stripping (Scharton-Kersten
et al, 2000). Epicutaneous peptide administration to tape-
stripped skin alone can result in the induction of CTL
responses to co-administered antigen (Seo et al, 2000). For
effective responses, relatively large amounts of peptide
(  100 nmol applied twice) were required. Tape-stripping
removes the stratum corneum, a significant barrier to large
molecular weight antigen (protein or peptide) penetration of
the skin. Tape-stripping also promotes local DC migration,
presumably in part via the release of IL-1 (Nishijima et al,
1997). As ODN have a molecular weight significantly in
excess of 500, a commonly described size limit for
epicutaneous diffusion in the absence of occlusion or
barrier perturbation (Bos and Meinardi, 2000), we chose to
study the adjuvancy of such ODN when applied to tape-
stripped skin. We demonstrate here that the epicutaneous
administration of the ODN with peptide or protein antigen
promotes the rapid and robust induction of CTL. CTL can
be detected ex vivo 6 d after a single administration of
antigen. These CTL have in vivo activity as detected by their
ability to inhibit cognate-antigen expressing tumor growth.
Peptide-specificity of the inhibition of tumor growth con-
firms that the adjuvant effect of the ODN results in the
generation of functional CTL and that tumor growth
inhibition is not due to other forms of ODN-mediated
immune stimulation such as NK cell activation. Although CT
(at 25 mg or  0.3 nmol, a dose limited by toxicity) is also
able to promote CTL priming to epicutaneous antigen
following tape-stripping (Kahlon et al, 2003), the ODN-1826
(at 500 mg or  80 nmol, with no toxicity observed) was
significantly more effective in generating CTL and in
promoting tumor immunoprophylaxis.
ODN-bearing CpG sequences initiate intracellular signal-
ing via the TLR9 receptor (Hemmi et al, 2000). Macro-
phages, B cells, and DC are known to express these
receptors. Although keratinocytes have been shown to
internalize ODN (Noonberg et al, 1993), they are not known
to express the TLR9 receptor. Thus epidermal or dermal DC,
are the most likely target cells of these reagents following
epicutaneous administration. The upregulation of the DC
co-stimulatory molecules CD86 and CD80 in draining-
lymph nodes by epicutaneous CpG ODN (1826) is con-
sistent with this (Fig 2C). Interestingly, an ODN sequence
originally designed for c-myc antisense therapy demon-
Figure 4
Effect of ODN on the generation of CTL by epicutaneous immunization with either peptide or protein antigen. (Panel A) Epicutaneous
immunization of mice with protein in the presence of CpG sequences results in the appearance of peptide-specific CTL in the peripheral blood as
soon as 6 d after a single epicutaneous immunization and is enhanced following boosting at 1 wk. Mice were immunized epicutaneously with
ovalbumin protein (500 mg) and 500 mg ODN (either 6295, 1826 or the respective non-CpG ODN controls, 6300 or 1982). Representative dot-plots of
peripheral blood lymphocytes from individual mice after a single immunization on day 6 and again, following a boost 1 wk after immunization (day
12). The numbers represent the percent Kb-OVA-specific CD8þ T cells among all CD8þ T cells detected. The figure is representative of two
independent experiments. (Panel B) Mice were immunized epicutaneously with either ovalbumin protein (500 mg––left panel) or OV8 peptide (25 mg––
right panel) and 500 mg ODN (either 6295 or 1826) as indicated, and boosted once. Splenocytes were harvested 1 wk later, re-stimulated in vitro
once, and CTL activity against a tumor cell line expressing OVA (EG7) or a control cell line (EL4) was determined. Each data point represents the
average CTL activity of three individual mice and error bars represent SEM. The optimal ODN sequence for the induction of CTL to epicutaneous
protein immunization (ODN-6295) differed from the optimal sequence for peptide immunization (ODN-1826). The data are representative of three
independent experiments.
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strated a differential adjuvant activity when compared with
ODN-1826 in peptide and protein immunization. Although
this sequence was only minimally effective in promoting
immune responses to co-administered peptide, it demon-
strated enhanced activity, when compared with ODN-1826
in inducing responses to co-administered protein (Fig 4).
Thus sequence-specific effects can be induced by ODN
when applied onto the skin. Indeed, ODN have been
classified into Type A and Type B, based on sequence
and putative target cell type (Krieg, 2002). For example, the
presence of poly-G motifs at the 50 and 30 ends and a
phosphodiester palindromic CpG-containing sequence has
been shown to preferentially activate NK cells and induce
IFNa production in human plasmacytoid DC precursors
(Krug et al, 2001). Likewise, a CpG sequence containing
poly-G motifs was optimal for the regression of melanomas
in mice (Ballas et al, 2001). In this regard, the ODN-6295
sequence (50-TAACGTTGAGGGGCAT-30) contains a CpG
sequence (underlined) as well as a four-mer poly-guanine
sequence (shaded) not present in ODN-1826 (50-TCCAT-
GACGTTCCTGACGTT-30). The presence of plasmacytoid
DC in inflammatory skin disease has recently been
documented (Farkas et al, 2001). Whether the poly-G
sequence present in ODN-6295 underlies this ODN’s
differential ability to enhance responses to epicutaneous
protein administration and whether this reflects the activa-
tion of a differential subgroup of DC such as plasmacytoid
DC remains to be determined. The differential adjuvant
effect of the tested ODN sequences on peptide or protein
antigen further suggests that the molecular and perhaps
cellular pathways by which epitopes from peptide antigen
and protein antigen are ultimately displayed on skin-derived
antigen-presenting cells that prime CTL differ. Regardless of
mechanism, the ability to induce potent CTL responses to
epicutaneously administered protein antigens has the
advantage of allowing the simultaneous induction of
CD4þ T helper responses important in the optimal control
of viral infections (Matloubian et al, 1994) and tumor growth
(Schuler-Thurner et al, 2002).
Tape-stripping is a cheap and readily performed proce-
dure that elicits minimal discomfort. It elicits less discomfort
than percutaneous needle puncture (Singer et al, 1998).
Parenteral administration of CpG sequences can be
associated with side-effects including extramedullary he-
matopoeisis (Sparwasser et al, 1999), antigen-independent
expansion of the naı¨ve and memory T cell compartment
(Davila et al, 2002), and exacerbation of auto-immune
disease (Miyata et al, 2000). As we could not detect an
immunostimulatory effect following contralateral CpG
administration, targeting CpG sequences to cutaneous DC
by epicutaneous administration may minimize these risks.
Although CT and modified enterotoxins have been used to
induce protective humoral and cellular immunity by the
epicutaneous route, robust CTL induction has either not
been demonstrated (unmodified enterotoxins) or whole CT
has been used. The known toxicities of CT continue to make
handling cumbersome and are dose limiting. The efficacy of
ODN sequences in epicutaneous immunization demon-
strated here for both peptide and protein may thus be a
significant advance in the design of simple and effective
epicutaneous vaccine technologies.
Materials and Methods
Animals and cell lines C57BL/6 mice were obtained from Charles
River Laboratories (Wilmington, Massachusetts) and held in a
specific pathogen-free environment. All animal experiments were
approved by the Animal Care Committee of the University of British
Columbia. EL4 thymoma and the E.G7-OVA cells (EL4 transfected
to express OVA, here termed EG7) (Carbone and Bevan, 1990)
were obtained from the American Type Culture Collection
(Manassas, Virginia) and cultured in complete medium (CM)
consisting of RMPI 1640 medium (Invitrogen, Burlington, Ont.,
Canada) supplemented with penicillin G (100 U per mL),
streptomycin sulfate (100 mg per mL), 5  105 M b-mercaptoetha-
nol and 10% fetal calf serum (FCS).
Immunizations, cytotoxicity assay, and tumor growth assay
For the induction of CTL, female C57BL/6 mice (routinely 5–6-wk
old) were immunized by the application of antigen with or without
adjuvant in phosphate-buffered saline (PBS) to tape-stripped ears.
For tape-stripping, mice were anesthetized by intraperitoneal
injection of ketamine plus xylazine. The ear skin on the dorsal
and ventral sides was then tape-stripped 10 times (using Scotch
Brand 3710 adhesive tape, 3M, Minnesota). To ensure functional
disruption of the epidermal barrier, the surface was next wiped
once with acetone. Antigen and adjuvant were then immediately
applied. Adjuvants consisted of CT (Sigma, St Louis, Missouri), or
one of following phosphorothioate-modified ODN: ODN-1826 (50-
TCCATGACGTTCCTGACGTT-30) (Chu et al, 1997) or the control
sequence ODN-1982 (50-TCCAGGACTTCTCTCAGGTT-30), ODN-
6295 (50-TAACGTTGAGGGGCAT-30) (Mui et al, 2001) or a control
sequence (ODN-6300) for ODN-6295 that maintains the same base
composition and four guanosine sequences but disrupts the CpG
motif (500-TAAGCATACGGGGTGT-30). ODN were purchased from
Avecia Biotechnology (Milford, Massachusetts) or Trilink Bio-
technologies Inc (SanDiego, California), dissolved in PBS and
stored at 201C until use. ODN were evaluated for endotoxin
contamination by suppliers and were considered endotoxin free
(o1 EU per mg). Antigen consisted of OVA (OVA V, Sigma,
Missouri) or peptide (OV8 or 2C, see below) as indicated. To boost
the response, the same procedure was applied to the contralateral
ear 1 wk later. Mice were euthanized at day 14. OVA-specific CTL
were detected immediately ex vivo using fluorescently labeled Kb-
OVA class I MHC tetramers (Altman et al, 1996). For tetramer
analysis of peripheral blood, samples (routinely 100 mL) were
obtained by saphenous vein puncture, depleted of red blood cells
and analyzed by fluorescence cytometry. To generate CTL for
functional assays, 5  106 splenocytes depleted of red blood cells
were stimulated with 2  106 irradiated E.G7-OVA cells (25,000
rad) and cultured in 10 mL CM for 5 d. Human rIL-2 (20 IU per mL)
(Pharmingen, California) was added on day 3. Chromium release
assays were carried out using 51Cr-labeled E.G7-OVA cells, or EL4
cells as targets. Plates were incubated for 4 h at 371C. Super-
natants were collected and g-radiation was measured. Specific
lysis of target cells was calculated using the formula (release by
CTLmedium release)/(detergent releasemedium release)  100.
Spontaneous release from target cells was always under 15%. For
tumor growth assays, mice were immunized by tape-stripping for 2
consecutive weeks (day 0 and 7). Blood was sampled on day 12.
On day 14, EG7 tumor cells (5  106) were injected subcutaneously
into the left flank of immunized mice. The tumor size was assessed
every second day by taking repeated perpendicular measurements
using digital calipers (Mitutoyo, Mississauga, Ont., Canada). Tumor
volumes were calculated using the standard formula for ellipsoid
tumor volumes, (length  width2)/2 where, by convention, width
was taken as the shorter of the two measurements.
Enzyme-linked immunospot (ELISpot) assays A standard cyto-
kine-specific ELISpot assay was used to detect CTL precursor
activity ex vivo as described (Miyahira et al, 1995). Briefly, cells
from the skin draining lymph nodes (axillary, cervical, and inguinal)
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and splenocytes were incubated in CM with or without 1 mg per mL
OV8 peptide and with the addition of 20 IU per mL human rIL-2 for
20 h. As a positive control, cells were stimulated with 25 mg per mL
concanavalin A. Cells were seeded onto nitrocellulose 96 microwell
plates (Millipore, Bedford, Massachusetts) coated with anti-mouse
interferon (IFN)g capture antibody (R4-6A2, Pharmingen). Biotiny-
lated anti-IFNg detection antibody (XMG 1.2, Pharmingen) was
then used to detect spot-forming cells (SFC) followed by the
addition of streptavidin-alkaline phosphatase (Bio-Rad, Hercules,
California) and 5-bromo-4-chloro-3 indolyl phosphate/nitroblue
tetrazolium substrate (Biorad). Spots were enumerated with the
aid of a stereo microscope. Values are expressed as the number of
peptide-specific SFC and were obtained by subtracting the
number of spots obtained without peptide from those obtained
with peptide stimulation per million cells. Values represent the
average of duplicate wells.
Cytoﬂuorometric analysis Three-channel fluorescence-activated
cell sorting (FACS) analysis was performed on a FACScalibur flow
cytometer (Becton Dickinson, San Jose, California) using Cell
Quest software (Becton Dickinson). Briefly, 200,000 cells were
analyzed after staining with appropriate antibodies or fluoro-
chrome-labeled class I MHC tetramer. Phycoerythrin (PE) labeled
Kb-OVA tetramers were purchased from Beckman Coulter Im-
munomics (San Diego, California). Antibodies to CD8a (clone YTS
169.4) were from Cedarlane (Hornby, Canada).
Dendritic cell preparation and analysis To quantitate the
expression of co-stimulatory molecules on DC, the ODN (500 mg)
were applied to the ears and draining lymph nodes were collected
20 h later. Single-cell suspensions were prepared by treating the
lymph nodes of mice with 1 mg per mL of collagenase D
(Boehringer Mannheim, Indianapolis, Indiana) supplemented with
40 mg per mL DNAse (Boehringer, Mannheim) and 10 mM EDTA.
DC were enriched using anti-CD11c mAb-coated microbeads
(MACS; Miltenyi Biotec, Auburn, California). Cells were incubated
on ice with anti-FcR mAb (2.4G2; American Type Culture Collec-
tion, Rockville, Maryland) to block Fc binding sites. Cells were
stained with APC-labeled anti-CD11c (HL3), FITC-labeled anti-
CD80 (16-10A1), and PE-labeled CD86 (GL1), all from Pharmingen.
Live CD11chi cells were gated for further analysis.
Peptide synthesis The Kb-restricted peptide OV8 (SIINFEKL) and
the control Kb-restricted peptide 2C (SIYRYYGL) (Udaka et al,
1996) were prepared using Fmoc chemistry, purified by reverse
phase high-performance liquid chromatography to 480% purity at
the Nucleic Acid and Peptide Synthesis Facility of the University of
British Columbia.
Statistical analysis Groups were compared using two-tailed
Student’s t tests or the Kruskal–Wallis test, with post hoc multiple
comparisons where indicated. Results were analyzed and dis-
played using Prism 3 (GraphPad software, San Diego, California).
The tumor survival curves were analyzed using SAS statistical
software and the proc mixed procedure.
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